Last reviewed · How we verify
Controlled withdrawal of beta-blockers
Controlled withdrawal of beta-blockers is a clinical protocol that gradually reduces beta-blocker dosing to safely discontinue the medication and minimize rebound hypertension and tachycardia.
Controlled withdrawal of beta-blockers is a clinical protocol that gradually reduces beta-blocker dosing to safely discontinue the medication and minimize rebound hypertension and tachycardia. Used for Safe discontinuation of beta-blocker therapy in patients requiring medication cessation, Prevention of rebound hypertension and tachycardia upon beta-blocker withdrawal.
At a glance
| Generic name | Controlled withdrawal of beta-blockers |
|---|---|
| Sponsor | Fundación para la Investigación del Hospital Clínico de Valencia |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Beta-blockers work by blocking adrenergic receptors, reducing heart rate and blood pressure. Abrupt discontinuation can cause a sudden surge in sympathetic activity, leading to rebound hypertension, tachycardia, and angina. Controlled, gradual tapering allows the cardiovascular system to readjust to normal sympathetic tone without acute adverse events.
Approved indications
- Safe discontinuation of beta-blocker therapy in patients requiring medication cessation
- Prevention of rebound hypertension and tachycardia upon beta-blocker withdrawal
Common side effects
- Rebound hypertension
- Rebound tachycardia
- Angina pectoris
- Myocardial infarction (in high-risk patients)
Key clinical trials
- Mindfulness Therapy for Chronic Migraine (PHASE4)
- Evaluation of Early CRRT InTerventions in Patients With ECMO(ELITE) (PHASE4)
- Pilot Study on Withdrawal of Spironolactone Among Heart Failure With Improved Ejection Fraction (NA)
- β-blockers Withdrawal in Patients With HFpEF and Chronotropic Incompetence: Effect on Functional Capacity (Preserve-HR) (PHASE4)
- Midodrine and Albumin in Patients With Refractory Ascites (PHASE3)
- Withdrawal of Medication in Recovered DCM (NA)
- Systematic Withdrawal of Neurohumoral Blocker Therapy in Optimally Responding CRT Patients (PHASE4)
- A Pilot Feasibility Study in Recovered Heart Failure (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |